Neurotoxicity is not uncommon in patients with melanoma treated with immune checkpoint inhibitors such as nivolumab and pembrolizumab, but it may be more common in patients treated with nivolumab plus a CTLA-4-blocking antibody such as ipilimumab, a study published in the journal Annals of Oncology has shown.
Read more here.
Study mentioned:
Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2016 Oct 25. doi: 10.1093/annonc/mdw558.
No comments:
Post a Comment